Astria Therapeutics, Inc. (ATXS) Misses Q3 EPS by 13c

Astria Therapeutics, Inc. (NASDAQ: ATXS) reported Q3 EPS of ($0.55), $0.13 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $706 thousand versus the consensus estimate of $12.8 million.

For earnings history and earnings-related data on Astria Therapeutics, Inc. (ATXS) click here.

You May Also Be Interested In

• Yatsen Holding (YSG) Reports Q2 Loss of $0.16
• GitLab Inc (GTLB) Tops Q2 EPS by 7c, Beats on Revenue
• Kontoor Brands sets Helly Hansen revenue target above $1.1B by 2030